Enzium
An early-stage diagnostics company
Monday, March 14, 2016
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
Enzium is a post-revenue, early-stage diagnostics company with a proprietary reagent platform that unleashes the power of proteases as biomarker signatures of disease.
Proteases are involved in infectious diseases, cancer, neurological diseases and any condition that causes inflammation. Protease signatures can differentiate even very closely related conditions. But existing reagents only give partial information (antibodies) or are insufficiently robust for routine clinical use (FRET). Also, Pharma companies have lost billions of dollars on late-stage protease inhibitor drug failures that may be preventable with better diagnostics.
Enzium currently serves global pharma, academic and laboratory researchers via direct sales and co-marketing with distribution partners. EnSens reagent kits follow the same workflow as FRET and are easier to use than antibodies. Each kit contains proprietary substrate, dye and buffer. Enzium currently manufactures 11 substrates, each available in 4 kit formats. And with custom syntheses, customers can finally measure the activity of 1000's of individual proteases-- impossible with existing technologies.
Enzium is collaborating with diagnostics companies and laboratories to accelerate short-term growth via access to clinical samples, customers and sales channels. Longer-term ROI is driven by internal development of select assays with existing reimbursement and clear unmet need, for example guiding therapy selection for Inflammatory Bowel Disease.
3 Major Issues
|
- A hybrid business model is proposed with three separate revenue streams phasing in over time: reagent sales via distributors, clinical diagnostics partnerships (sub-licensees), and internal development programs. Is this the best way to monetize the broadly applicable EnSens reagent platform?
- What is the best strategy to manage focus and organizational structure/capabilities with multiple separate revenue streams.
- Protease discovery research is ongoing in academia and in industry. What is the best way to engage in fundamental research to discover unique disease signatures? We would like to own or have exclusive access to any associated IP.
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Steve Popielarski PhD, CEO of Enzium, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.
9:00 - Open discussion: members and guests
|
 |
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
